Toronto, Ontario–(Newsfile Corp. – January 19, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today it has signed a Memorandum of Understanding (“MOU”) with the Multidisciplinary Association for Psychedelic Studies (MAPS) to explore…


Previous articleTwo thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
Next articlePsychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II